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Background
Hepatitis C virus (HCV) is a global infection, with
an estimated 170 million people affected.
1 The geo-
graphical distribution is of some interest as it gives
clues as to the history and transmission of the virus.
It appears there are endemic strains, which have
persisted in specific locations for many centuries.
These can be readily identified by viral geno-
type—for example, Genotype 2 is a strain which
evolved in West Africa, while Genotype 6 evolved
in South East Asia.
2 In the last century, there have
been iatrogenic outbreaks leading to a massive
spread of specific subtypes in countries such as
Egypt (Genotype 4A).
3 There was also global
spread of certain strains, most notably Genotype 1
within Europe and North America, and more
recently Genotype 3A in European intravenous
drug user (IDU) populations.
4
HCV heterogeneity is huge, based on its capacity
to develop mutation through its error-prone poly-
merase, and its very long co-evolutionary history
with man. This is a major challenge for drug
design and vaccines. Clinically, genotypic informa-
tion on the virus is of major importance in defining
response to conventional as well as newer
therapies.
1,4
Chronic HCV infection is now a leading cause of
hepatic failure requiring transplantation in the west.
Cirrhosis associated with HCV is also linked to the
development of hepatocellular carcinoma, although
unlike hepatitis B virus (HBV) this does not occur in
pre-cirrhotic states. Chronic HCV infection is also
associated with a number of extra-hepatic diseases,
linked to B cell hyper-activation and potentially also
chronic antigenemia—most notably mixed essential
cryoglobulinaemia.
5
Acute infection and host defence
Acute hepatitis C is actually a rare clinical presen-
tation, despite the widespread nature of the virus.
Typically, acute hepatitis is mild and may be clinic-
ally very subtle, with a delay of several weeks
before a rise in alanine transaminase (ALT) is seen.
HCV infection may set up persistence in the majority
of those infected; although interestingly, upto 30%
may clear the virus and remain negative by poly-
merase chain reaction (PCR) tests of blood there-
after. This clearance typically occurs within the
first 6 months of infection. Some patients show a
‘yo-yo’ course of infection, with partial control
over this period, followed by persistence. This may
be due in some cases to super-infection or infection
with multiple strains.
6
A great deal of effort has been spent trying to
define the mechanisms by which this robust immun-
ity is mediated. Studies of cohorts such as women
in Ireland and Germany, who were infected with
contaminated blood products in Rhesus disease
prevention programmes have been particularly
useful here as the viral sequence and timing of
infection were very well defined.
7 From such stu-
dies, as well as studies of prospectively followed
cohorts, the following features have emerged:
1. Clearance of the virus is typically associated with a
robust T cell response, comprising both CD4+ and
CD8+ T cell responses, which is sustained over several
weeks.
8
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ported by HLA association with outcome—including
HLA B27, HLA B57 (both also protective in
human immunodeficiency virus), HLA A3 and HLA
DR11.
7
3. There is a major role for innate responses. In particular,
polymorphisms in the interferon lambda gene IL28B
have been strongly associated with outcome, as they
are with treatment response (see below).
9
4. Antibody responses do develop, although effective
neutralization is limited by the rapid emergence of
escape mutants in the envelope gene.
10 Escape
mutation also limits the efficacy of T cell responses.
11
5. Progression to chronicity is associated with a
marked attenuation of circulating cellular immune
responses, although within liver tissue these may be
retained and contribute to immune-mediated
pathology.
Viral replication
The development of successful treatments for
HCV has relied upon efforts to understand the viral
life cycle in vitro and in vivo. While there remain
no intact small animal models for replicating HCV
(although partial mouse models exist
12), much
progress has been made in in vitro culture model
systems and with it has come a massive increase
in our understanding of host–virus interactions.
Current HCV culture systems arose from the subge-
nomic replicons developed a decade ago. These
required specific hepatocyte cell lines (Huh-7
derived) and tissue culture adaptation of the subge-
nomic constructs. A major breakthrough in this
area came with the development of strains derived
from a Japanese genotype 2 virus (JFH-1), which
can complete a full replication cycle and produce
new infectious virus to good titres in vitro.
13 These
systems also rely on specific modified hepatocyte
cell lines, which lack some innate signalling
programmes.
These systems have revealed:
1. The key cell entry factors for HCV, which include
CD81, scavenger receptor class B1 (SRB1), low-density
lipoprotein receptor (LDLR) and the tight junction-
associated proteins human occludin (OCLN) and
claudin-1 (CLDN1).
14
2. The tight linkage between viral replication and
modification of the lipid handling of the hepatocyte,
including the generation of lipid droplets.
15
3. The ability of the virus to evade host defence, includ-
ing the significant impact of non structural protein 3
and 4A (NS3 and NS4A) in cleavage of the host
signalling molecule Cardif/mitochondrial anti-viral
signalling proteins (MAVS), disrupting early events in
virus recognition.
16
4. The impact of antivirals (including interferons) in vitro,
including the development of escape mutations in
response to selection pressure.
Vaccines
No effective preventive vaccine for HCV exists
currently.
17 Given the problems of viral diversity
described above, a conventional vaccine based
on anti-envelope antibodies (as is effective in HBV
infection) is unlikely to be easily generated. Much
effort has gone into the development of vaccines
to stimulate cellular immunity. These still need to
overcome the problem of viral diversity, but the
hope is that such responses may target a sufficient
range of viral proteins to limit escape mutations.
Such vaccines are still in the early phase of develop-
ment both for prevention and also as potential thera-
pies. In the latter case, the published data suggest
only a limited or transient response to date, but
diverse strategies are still under investigation.
18,19
Therapy
Up until this year, standard therapy for HCV has
been a combination of Pegylated Interferon alpha
(PegIFNa) and Ribavirin. The actual mechanism of
action of this combination is not clear, especially the
role of Ribavirin, which has weak antiviral activity.
Overall, treatment has incrementally improved
over the last decade and PegIFNa/Ribavirin can
lead to a sustained virologic response (SVR) i.e. un-
detectable virus 6 months beyond the end of
therapy, in 60–70% of patients with Genotypes 2
and 3 (after 6 months therapy), but in <50% of
patients with Genotype 1 (requiring 12 months
therapy).
It has long been known that a variety of factors
contribute to outcome, including host genetics.
What was striking from recent studies using
genome-wide scans is the specific role of poly-
morphisms in IL28B.
9,20 The actual role of this
cytokine in vivo is not yet clear, indeed the impact
of the polymorphism is also not fully understood.
However, genotyping for IL28B can provide
additional information (along with other clinical
factors such as viral load, fibrosis, co-morbidities),
which can aid stratification for therapy. Trials of
lambda interferon—which has a more restricted
side-effect profile than the alpha form—are
underway (reviewed in Ref.
21).
New therapies with agents focusing on specific
viral proteins such as protease and polymerase are
now emerging. Two protease inhibitors, Telapravir
and Bocepravir, have now undergone extensive
30 P. Klenerman and P.K. Guptatrials and have recently been licensed.
22–25 Current
treatment strategies require co-administration
with PegIFNa/Ribavirin—monotherapy is associated
with the rapid emergence of drug resistance.
These regimens have shown improved efficacy com-
pared with current standard of care (60–75% SVR),
with potentially shorter treatment courses, although
these are restricted to Genotype 1. Interestingly, they
also show good efficacy in previous unsuccessfully
treated patients (60–65% SVR). Combination therapy
will be of major interest in the future and the possi-
bility of interferon-free regimens has been raised,
if multiple specific antivirals are sufficiently potent
(Figure 1). Once again the circulating viral diversity
and the capacity of the virus to adapt rapidly to new
selective forces are major hurdles to overcome.
Future directions
Further host genetics, so fruitful so far in this infec-
tion, may give important clues as to viral clearance
mechanisms, while further viral genetics will
remain important to define mechanisms of
resistance to therapy and vaccines. The explosion
in next-generation sequencing should help both
endeavours. The efforts to optimize new treatment
regimes as new antivirals emerge will occupy many
in clinical research programmes. It will be important
to learn from the HIV experience, where com-
bination therapies have proven so success-
ful—regimens which only emerged as a result of
substantial collaborative effort. This may be aided
by the further development of small animal
models. The future does look bright for new thera-
pies for HCV although in this wave of enthusiasm
it should not be forgotten that many in the global
epidemic—both in the west and in the developing
world—will not have ready access to such
treatments in their current forms.
Funding
Wellcome Trust Fellowship awards (WT091663MA
and WT096212AIA to P.K. and P.G.); NIHR
Biomedical Research Centre (Oxford); The Oxford
diagnostics infection model s stems p diagnostics infection model s stems p
20 30 20 30
1990 2011 ? e r u t u F 0 0 0 2
VIROLOGY
Virus 
Discovered
In Vitro
Replicon
Cell culture
Models
(Full replication)
In vivo
murine model
(entry only)
In vivo
murine model
(full replication)
IMMUNITY
Antibodies for 
T cell protection
in natural
Protective
vaccines in 
Early phase 
prophylactic and 
thera eutic
Broadly cross-
reactive NAbs
and T cell based  y
vaccines vaccines
THERAPY Interferon
Interferon
&
Ribavirin
PEG-Interferon
&
Ribavirin
PEG-Interferon
&
Ribavirin
&
Protease Inhibitor
Multiple antiviral 
drugs.
Interferon-free
regimens
S
V
R
40-50
60-70
?
%
10
-
Figure 1. Timeline for advances in understanding HCV. The coloured blocks represent rough timelines for the key steps in
the fields of virology, immunology and therapy. The graph below indicates the approximate success rates for treatment
success using the regimens indicated (for Genotype 1). Success rates vary with genotype as well as a number of other
factors.
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